Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease

Anna Alisi; Sara Ceccarelli; Nadia Panera; Federica Prono; Stefania Petrini; Cristiano De Stefanis; Marco Pezzullo; Alberto Tozzi; Alberto Villani; Giorgio Bedogni; Valerio Nobili

doi:10.1371/journal.pone.0067160

Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease

Anna Alisi, Sara Ceccarelli, Nadia Panera, Federica Prono, Stefania Petrini, Cristiano De Stefanis, Marco Pezzullo, Alberto Tozzi, Alberto Villani, Giorgio Bedogni, Valerio Nobili

Ospedale Pediatrico Bambino Gesu

Research output: Contribution to journal › Article

Abstract

Atypical fibroblast growth factors (FGF) 21 and 19 play a central role in energy metabolism through the mediation of Klotho coreceptor. Contradictory findings are available about the association of FGF21 and FGF19 with nonalcoholic fatty liver disease (NAFLD) in humans. We investigated the association of serum FGF21, FGF19 and liver Klotho coreceptor with non-alcoholic steatohepatitis (NASH) and fibrosis in children with NAFLD. Serum FGF21 and FGF19 were measured in 84 children with biopsy-proven NAFLD and 23 controls (CTRL). The hepatic expression of Klotho coreceptor was measured in 7 CTRL, 9 patients with NASH (NASH+) and 11 patients without NASH (NASH-). FGF21 and FGF19 showed a tendency to decrease from CTRL (median FGF21 = 196 pg/mL; median FGF19 = 201 pg/mL) to NASH- (FGF21 = 89 pg/mL; FGF19 = 81 pg/mL) to NASH+ patients (FGF21 = 54 pg/mL; FGF19 = 41 pg/mL) (p2 = 0.87, p2 = 0.57, p2 = 0.67, p

Original language	English
Article number	e67160
Journal	PLoS One
Volume	8
Issue number	6
DOIs	https://doi.org/10.1371/journal.pone.0067160
Publication status	Published - Jun 26 2013

Fingerprint

ASJC Scopus subject areas

Agricultural and Biological Sciences(all)
Biochemistry, Genetics and Molecular Biology(all)
Medicine(all)

Cite this

Alisi, A., Ceccarelli, S., Panera, N., Prono, F., Petrini, S., De Stefanis, C., Pezzullo, M., Tozzi, A., Villani, A., Bedogni, G., & Nobili, V. (2013). Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. PLoS One, 8(6), [e67160]. https://doi.org/10.1371/journal.pone.0067160

Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. / Alisi, Anna; Ceccarelli, Sara; Panera, Nadia; Prono, Federica; Petrini, Stefania; De Stefanis, Cristiano; Pezzullo, Marco; Tozzi, Alberto ; Villani, Alberto; Bedogni, Giorgio; Nobili, Valerio.

In: PLoS One, Vol. 8, No. 6, e67160, 26.06.2013.

Research output: Contribution to journal › Article

@article{1b319553611a477a89ea873d563cb56c,

title = "Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease",

abstract = "Atypical fibroblast growth factors (FGF) 21 and 19 play a central role in energy metabolism through the mediation of Klotho coreceptor. Contradictory findings are available about the association of FGF21 and FGF19 with nonalcoholic fatty liver disease (NAFLD) in humans. We investigated the association of serum FGF21, FGF19 and liver Klotho coreceptor with non-alcoholic steatohepatitis (NASH) and fibrosis in children with NAFLD. Serum FGF21 and FGF19 were measured in 84 children with biopsy-proven NAFLD and 23 controls (CTRL). The hepatic expression of Klotho coreceptor was measured in 7 CTRL, 9 patients with NASH (NASH+) and 11 patients without NASH (NASH-). FGF21 and FGF19 showed a tendency to decrease from CTRL (median FGF21 = 196 pg/mL; median FGF19 = 201 pg/mL) to NASH- (FGF21 = 89 pg/mL; FGF19 = 81 pg/mL) to NASH+ patients (FGF21 = 54 pg/mL; FGF19 = 41 pg/mL) (p2 = 0.87, p2 = 0.57, p2 = 0.67, p",

author = "Anna Alisi and Sara Ceccarelli and Nadia Panera and Federica Prono and Stefania Petrini and {De Stefanis}, Cristiano and Marco Pezzullo and Alberto Tozzi and Alberto Villani and Giorgio Bedogni and Valerio Nobili",

year = "2013",

month = jun

day = "26",

doi = "10.1371/journal.pone.0067160",

language = "English",

volume = "8",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "6",

}

TY - JOUR

T1 - Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease

AU - Alisi, Anna

AU - Ceccarelli, Sara

AU - Panera, Nadia

AU - Prono, Federica

AU - Petrini, Stefania

AU - De Stefanis, Cristiano

AU - Pezzullo, Marco

AU - Tozzi, Alberto

AU - Villani, Alberto

AU - Bedogni, Giorgio

AU - Nobili, Valerio

PY - 2013/6/26

Y1 - 2013/6/26

N2 - Atypical fibroblast growth factors (FGF) 21 and 19 play a central role in energy metabolism through the mediation of Klotho coreceptor. Contradictory findings are available about the association of FGF21 and FGF19 with nonalcoholic fatty liver disease (NAFLD) in humans. We investigated the association of serum FGF21, FGF19 and liver Klotho coreceptor with non-alcoholic steatohepatitis (NASH) and fibrosis in children with NAFLD. Serum FGF21 and FGF19 were measured in 84 children with biopsy-proven NAFLD and 23 controls (CTRL). The hepatic expression of Klotho coreceptor was measured in 7 CTRL, 9 patients with NASH (NASH+) and 11 patients without NASH (NASH-). FGF21 and FGF19 showed a tendency to decrease from CTRL (median FGF21 = 196 pg/mL; median FGF19 = 201 pg/mL) to NASH- (FGF21 = 89 pg/mL; FGF19 = 81 pg/mL) to NASH+ patients (FGF21 = 54 pg/mL; FGF19 = 41 pg/mL) (p2 = 0.87, p2 = 0.57, p2 = 0.67, p

AB - Atypical fibroblast growth factors (FGF) 21 and 19 play a central role in energy metabolism through the mediation of Klotho coreceptor. Contradictory findings are available about the association of FGF21 and FGF19 with nonalcoholic fatty liver disease (NAFLD) in humans. We investigated the association of serum FGF21, FGF19 and liver Klotho coreceptor with non-alcoholic steatohepatitis (NASH) and fibrosis in children with NAFLD. Serum FGF21 and FGF19 were measured in 84 children with biopsy-proven NAFLD and 23 controls (CTRL). The hepatic expression of Klotho coreceptor was measured in 7 CTRL, 9 patients with NASH (NASH+) and 11 patients without NASH (NASH-). FGF21 and FGF19 showed a tendency to decrease from CTRL (median FGF21 = 196 pg/mL; median FGF19 = 201 pg/mL) to NASH- (FGF21 = 89 pg/mL; FGF19 = 81 pg/mL) to NASH+ patients (FGF21 = 54 pg/mL; FGF19 = 41 pg/mL) (p2 = 0.87, p2 = 0.57, p2 = 0.67, p

UR - http://www.scopus.com/inward/record.url?scp=84879468929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879468929&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0067160

DO - 10.1371/journal.pone.0067160

M3 - Article

AN - SCOPUS:84879468929

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e67160

ER -

Access to Document

10.1371/journal.pone.0067160